Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • DPP4 inhibitors may...

DPP4 inhibitors may increase risk of cholecystitis in T2 Diabetes patients: BMJ

Dr.Niharika Harsha BWritten by Dr.Niharika Harsha B Published On 2022-06-29T11:00:46+05:30  |  Updated On 29 Jun 2022 10:32 AM GMT
DPP4 inhibitors may increase risk of cholecystitis in T2 Diabetes patients: BMJ
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • koo
  • Email

Increased risk of Cholecystitis was found in Type 2 Diabetes patients who were using Dipeptidyl peptidase-4 inhibitors. The study was published in the journal, The BMJ 2022.Diabetes is a pandemic affecting a larger population across the globe. Multiple drugs were introduced to treat the condition either as monotherapy or as combination therapy. Of these Dipeptidyl peptidase-4 inhibitors...

Increased risk of Cholecystitis was found in Type 2 Diabetes patients who were using Dipeptidyl peptidase-4 inhibitors. The study was published in the journal, The BMJ 2022.

Diabetes is a pandemic affecting a larger population across the globe. Multiple drugs were introduced to treat the condition either as monotherapy or as combination therapy. Of these Dipeptidyl peptidase-4 inhibitors are commonly used for the management of Type 2 Diabetics. Recently concern was raised that Dipeptidyl peptidase-4 inhibitors may cause gall bladder or biliary diseases. So, researchers from the Peking Union Medical College Hospital, China conducted a study to examine the association between dipeptidyl peptidase-4 inhibitors and gallbladder or biliary diseases.

Also Read: Gastric Bypass better than Sleeve Gastrectomy for 10-Year Outcomes: JAMA

Zhang et al conducted a systematic review with pairwise and network meta-analysis to find the association. Using the keywords they conducted a search strategy in various databases like PubMed, EMBASE, Web of Science, and CENTRAL from inception until 31 July 2021. They included randomized controlled trials of adult patients with type 2 diabetes who received dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors compared with placebo or other antidiabetic drugs. The outcomes of measurement were gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases. The data were extracted independently and the quality of the studies was assessed by two reviewers. Using the Grading of Recommendations, Assessment, Development, and Evaluations framework (GRADE) approach, the quality of the evidence for each outcome was assessed. Pooled odds ratios and 95% confidence intervals were used for the meta-analysis.

Results:

  • 104 833 participants from 82 randomized controlled trials were included in the pairwise meta-analysis.
  • Dipeptidyl peptidase-4 inhibitors were significantly associated with an increased risk of the composite of gallbladder or biliary diseases and cholecystitis but not with the risk of cholelithiasis and biliary diseases when compared with placebo or non-incretin drugs.
  • The association was seen in diabetics using dipeptidyl peptidase-4 inhibitors for longer duration.
  • The meta-analysis revealed that dipeptidyl peptidase-4 inhibitors increased the risk of the composite of gallbladder or biliary diseases and cholecystitis compared with sodium-glucose cotransporter-2 inhibitors but not compared with glucagon-like peptide-1 receptor agonists. 

Thus, the researchers concluded that Dipeptidyl peptidase-4 inhibitors increased the risk of cholecystitis, in patients who are using them for longer duration. They further added that more attention has to be given while prescribing the drug due to the risk of cholecystitis.

For full article, click here:            Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials

BMJ 2022; 377 doi:

https://doi.org/10.1136/bmj-2021-068882

type 2 diabetes mellitusDipeptidylpeptidase-4 Inhibitorscholecystitisbiliary diseaseGallbladder disease
Source : The BMJ
Dr.Niharika Harsha B
Dr.Niharika Harsha B

    BDS, MDS

    Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X